|Bid||87.88 x 100000|
|Ask||87.88 x 100000|
|Day's Range||87.98 - 88.32|
|52 Week Range||79.28 - 93.54|
|PE Ratio (TTM)||13.71|
|Forward Dividend & Yield||1.06 (1.19%)|
|1y Target Est||N/A|
In this article, I will take a look at Fresenius Medical Care AG & Co KGaA’s (ETR:FME) most recent earnings update (30 June 2018) and compare these latest figures againstRead More...
Fresenius Medical Care AG said it completed the divestment of Sound Inpatient Physicians Holdings, selling the business to an investment consortium led by Summit Partners. The German company, which provides dialysis services, said the divestment will bolster its net income by about $752 million.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to better understand how you canRead More...
Germany's Fresenius Medical Care (FMC) (FMEG.DE) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval. The world's largest provider of kidney dialysis, FMC is banking on the alliance to lead to better ways of accessing patients' blood vessels, a delicate medical procedure that is part of providing life-saving dialysis, the company said in a statement on Monday. FMC will take a 19 percent stake in the privately held company.
BOSTON, June 11, 2018 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte's investigational human acellular vessel, HUMACYL®, available to more patients worldwide following approval of the product. HUMACYL is currently being investigated for vascular access for hemodialysis and may prove more effective than current synthetic grafts and fistula.
Cara said it has licensed worldwide rights — except in the U.S., Japan and South Korea — to commercialize Korsuva injection with VFMCRP, a joint venture between Vifor Pharma and Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS). The deal provides for a $50-million upfront cash payment to Cara and an equity investment of $20 million via share sales at $17 apiece.
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
Investors pursuing a solid, dependable stock investment can often be led to Fresenius Medical Care AG & Co KGaA (XTRA:FME), a large-cap worth €26.04B. Risk-averse investors who are attracted toRead More...
The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.
U.S. generic drugmaker Akorn (AKRX.O) is taking former suitor Fresenius (FREG.DE) to court after the German healthcare group cancelled their $4.75 billion (3.4 billion pounds) takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.
U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group cancelled their $4.75 billion takeover agreement. Akorn shares lost more than a third of their value on Monday, the day after Fresenius pulled out of a deal first announced last April. The German company cited evidence of misconduct in Akorn's reporting of drug development data to U.S. healthcare regulators.
dropped its planned $5 billion takeover of the generic drugmaker after a probe into possible data breaches by the U.S. Food & Drug Administration. Fresenius said it found "material" breaches of FDA1 data integrity rules as part of its own investigation into allegations levelled against the Lake Forest, Ill.-based Akorn earlier this year and offered to delay its proposed takeover if the group could supply information that would allow Fresenius to reconsider. The Germany company said Akorn declined that offer.